ERBB2 and cancer: Overall, among 83 evaluable HER2-expressing patients, 37 patients had an OR (ORR 31%; 95% CI 27.0–49.0), including 8 patients with biliary tract cancer (38%), 10 patients with colorectal cancer (38%), and 13 patients with other cancer types (36%).